【摘要】 目的：通过荟萃分析(Meta分析)系统评价基于多组学技术治疗心血管疾病(cardiovascular disease，CVD)的证据，为CVD患者提供治疗新方向。方法：系统检索中国生物医学文献数据库、中国知网等中文数据库，以及PubMed、Web of Science等外文数据库，2015年4月至2025年4月公开发表的基于多组学技术治疗CVD的相关文献，观测白细胞介素-6(interleukin-6，IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α，TNF-α)、甘油三酯(triglyceride，TG)、总胆固醇(total cholesterol，TC)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol，LDL-C)、高密度脂蛋白胆固醇(high-density lipoprotein cholesterol，HDL-C)、收缩压(systolic blood pressure，SBP)、舒张压(diastolic blood pressure，DBP)等研究指标以探索多组学技术对CVD的影响，选用Review Manager 5.4软件进行Meta分析，并采用Egger检验对发表偏倚进行分析。结果：最终纳入6篇文献，共纳入588例患者。Meta分析结果显示，基于多组学技术治疗组的CVD患者的TNF-α水平显著低于多组学技术应用之前的TNF-α水平(SMD=-0.78，95%CI：-1.10～-0.46，P<0.05)，且漏斗图呈对称状，发表偏倚可能性较小；而基于多组学技术治疗后，CVD患者的其他传统临床指标未出现明显改变，部分指标无统计学意义。结论：在治疗CVD中，多组学技术能够通过调控血管功能相关分子网络并下调促炎因子的表达，同时可能更多针对非传统通路。更多还原

【Abstract】 Objective Meta-analysis was used in order to systematically evaluate the evidence for multi-omics technology in treating cardiovascular disease (CVD) aiming to provide new treatment avenues for CVD patients.Methods A systematic search was conducted across Chinese databases (such as China Biology Medicine disc and China National Knowledge Infrastructure) and international databases (including PubMed and Web of Science) for literature published between April 2015 and April 2025 on multi-omics-based interventions for CVD.Research indicators such as interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α),triglyceride (TG),total cholesterol (TC),low-density lipoprotein cholesterol (LDL-C),high-density lipoprotein cholesterol (HDL-C),systolic blood pressure (SBP),diastolic blood pressure (DBP) were observed to explore the impact of multi-omics technology on cardiovascular diseases,and Review Manager 5.4 software was selected for Meta-analysis,and Egger’s test was used to Publication bias was analyzed.Results Six papers with a total of 588 patients were finally included.Meta-analysis results showed that the TNF-α level in the treatment group based on multi-omics technology was significantly lower than the TNF-α level before the application of multi-omics technology (SMD=-0.78,95% CI:-1.10 to-0.46,P<0.05).Moreover,the funnel plot exhibits symmetry,indicating a low likelihood of publication bias.And after the treatment based on multi-omics technology,the other traditional clinical indexes in patients with cardiovascular diseases did not show significant changes,and some of the indexes were not statistically significant.Conclusion In the treatment of cardiovascular diseases,multi-omics technology can be used to regulate vascular function-related molecular networks and down-regulate the expression of pro-inflammatory factors by modulating the vascular function-related molecular networks,while possibly targeting more non-traditional pathways.更多还原